Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 1, 2008, Pages 26.e1-26.e8

  Baseman, Janet G ^a   Kulasingam, Shalini L ^c   Harris, Tiffany G ^b   Hughes, James P ^a   Kiviat, Nancy B ^a   Mao, Constance ^d   Koutsky, Laura A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cervical cancer; human papillomavirus (HPV); screening

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; CELL TYPE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; FAMILY PLANNING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; PAPANICOLAOU TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UNITED STATES; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 45649084802     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.11.051     Document Type: Article

References (19)

1. Parkin D.M., Whelan S.L., Ferlay J., Raymond L., and Young J. Cancer incidence in five continents. vol VII (1997), IARC, Lyon, France
2. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
3. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists: ACOG Practice Bulletin No.: 61: human papillomavirus. Obstet Gynecol 105 (2005) 905-918
4. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 48 (1999) 6-29
5. Solomon D., Schiffman M., Tarone R., and ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93 (2001) 293-299
6. Stoler M.H., and Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285 (2001) 1500-1505
7. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
8. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: international biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87 (1995) 796-802
9. Schiffman M.H., Bauer H.M., Hoover R.N., et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85 (1993) 958-964
10. Wright Jr. T.C., Cox J.T., Massad L.S., et al. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287 (2002) 2120-2129
11. Kulasingam S.L., Hughes J.P., Kiviat N.B., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
12. Belinson J.L., Qiao Y.L., Pretorius R.G., et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 83 (2001) 439-444
13. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
14. Center for devices and Radiological Health, US Food and Drug Administration. Clinical Laboratory Improvement Methods; 2002. Accessed January 14, 2008. Available at: http://wwwn.cdc.gov/clia/chronol/aspy
15. An introduction to the bootstrap (1993), Chapman and Hall, New York 436.
16. Sasieni P.D., Cuzick J., and Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer: the National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 73 (1996) 1001-1005
17. Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
18. Goldie S.J., Kim J.J., and Wright T.C. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 103 (2004) 619-631
19. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52